Nyheter/Reuters/UCB Announces Positive Phase 3 Studies For Bimekizumab In Hidrade…UCB Announces Positive Phase 3 Studies For Bimekizumab In Hidradenitis Suppurativa9 dec. 202213:54 UTCUCBUCB SA UCB:UCB ANNOUNCES POSITIVE PHASE 3 STUDIES FOR BIMEKIZUMAB IN HIDRADENITIS SUPPURATIVA